|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMATOPOIESIS
From the Hematology/Oncology Section and
Transplantation Surgery Section, Biologic Resources Laboratory,
University of Illinois College of Medicine, Chicago.
Quiescence has been thought to be required for the retention of the
full biological potential of pluripotent hematopoietic stem cells
(PHSCs). This hypothesis has been challenged recently by the
observation that all murine PHSCs cycle continuously and constantly
contribute to steady-state blood cell production. It was asked
whether these observations could be extrapolated to describe
hematopoiesis in higher mammals. In this series of experiments, the
replicative history of PHSCs was examined in baboons by continuously administering bromodeoxyuridine (BrdU) for more than 85 weeks. The
results indicate that under steady-state conditions, PHSCs remain
largely quiescent but do cycle, albeit at a far lower rate than
previously reported for rodent PHSCs. BrdU-labeled cycling PHSCs and
progenitor cells were shown to have an extensive proliferative capacity
and to contribute to blood cell production for prolonged periods
of time. The proportion of PHSCs entering cell cycle could, however, be
rapidly increased by the in vivo administration of granulocyte-colony
stimulating factor. These data indicate that during
steady-state hematopoiesis, baboon PHSCs require prolonged periods of
time to cycle and that the proportion of PHSCs in cycle is not fixed
but can be altered by external stimuli. The relative quiescence of
PHSCs observed in this nonhuman primate model, in contrast to murine
PHSCs, might explain the current barriers to genetic modification and
ex vivo expansion of human PHSCs.
(Blood. 2001;97:3061-3068) Mammalian blood cell production is a tightly
regulated process in which a hierarchy of cycling hematopoietic stem
cell populations contributes to active hematopoiesis.1-5
The formed elements of blood ultimately originate from rare pluripotent
hematopoietic stem cells (PHSCs), which are capable of self-renewal and
differentiation into cells belonging to each hematopoietic
lineage.6,7 PHSCs contribute to steady-state hematopoiesis
and respond to a variety of stressful conditions without actually
depleting their number. It is commonly believed that PHSCs remain
quiescent during steady-state hematopoiesis and that stem cell
quiescence plays a pivotal role in determining the self-renewal and
proliferative potential of PHSCs.8,9
In 1965, Kay10 postulated that only a few PHSC clones
actively contribute to blood cell production at any given time and that
only after exhaustion of these active clones would additional PHSCs
self-replicate and actively contribute to blood cell production. Experimental evidence supporting this clonal succession hypothesis was
first gained by studies of the contribution of murine blood cell
production by PHSCs that had been genetically modified by retroviral
vectors.11,12 The contribution of individual PHSCs to
blood cell production was monitored by tracking retroviral integration
sites in mature blood cells. Abkowitz and coworkers13 also
addressed this hypothesis by performing stem cell transplants in female
cats who were heterozygotes for the X-linked gene glucose 6-phosphate
dehydrogenase. They observed wide fluctuations in clonal
contributions to hematopoiesis following initial engraftment but found
that long-term reconstitution was due to a limited number of stem cell
clones.13 The validity of such reconstitution assays as an
appropriate test of the clonal succession hypothesis has been
questioned since the kinetics of hematopoietic reconstitution following
stem cell transplantation bears little resemblance to the events
occurring during steady-state hematopoiesis.14
The clonal succession hypothesis has recently been challenged by
studies in which the proliferation history of PHSCs has been directly
analyzed by monitoring the incorporation of a nucleotide analogue into
the DNA of cycling cells in mice.15-17 The incorporation of bromodeoxyuridine (BrdU) into primitive hematopoietic progenitors was assessed by exposing mice to BrdU in order to label the nuclei of
dividing cells. These studies were further aided by the phenotypic characterization and identification of PHSCs. These studies indicate that murine PHSCs enter the cell cycle in an asynchronous manner and
that virtually all PHSCs slowly divide over a period of 1.5 to 3.0 months.16,17 Many murine PHSCs were found to
contribute simultaneously to steady-state blood cell production.
Moreover, a large fraction of murine PHSCs could be driven to
self-replicate prior to their mobilization into the peripheral blood
(PB) if stressed by the in vivo administration of
cyclophosphamide and granulocyte-colony stimulating factor
(G-CSF).18
Since important differences are known to exist between the PHSCs of
large animals and rodents,19 we attempted to study PHSC quiescence during steady-state hematopoiesis and following stress induced by the administration of G-CSF. The studies were pursued owing
to the uncertainty of whether the conclusions drawn from rodent
experimentation could be used to further expand our understanding of
human hematopoiesis. As the subject of these studies, we chose nonhuman
primates in which steady-state blood cell production as well as
engraftment kinetics following stem cell transplantation closely
resembles that of humans.7,20,21 We also used a
noninvasive method to track cycling PHSCs in vivo by monitoring the
incorporation of BrdU into cycling PHSCs.16,17 Since BrdU
is incorporated into the genomic DNA of dividing cells, bound BrdU can
be traced in successive generations of dividing cells.22
The present data indicate that a large fraction of PHSCs in baboons
remains quiescent during steady-state conditions but that during an
85-week period of observation, most PHSCs do indeed cycle at an
apparently much slower rate than is observed in murine PHSCs. The
fraction of PHSCs cycling at any one time does not, however, appear to
be fixed since PHSC cycling in vivo can be rapidly increased by the administration of G-CSF.
Nonhuman primate model
Continuous administration of BrdU to baboons
Stem cell mobilization and collection G-CSF (a gift of Amgen, Thousand Oaks, CA) was administered at a dose of 100 µg/kg as daily subcutaneous injections for 5 days in the lateral aspect of the thighs of 2 additional animals (PA6243 and PA5957). This dose of human recombinant G-CSF has previously been shown to be optimal for the mobilization of baboon hematopoietic stem cells that are capable of reconstituting hematopoiesis in lethally irradiated nonhuman primates.20,21 Starting 2 days prior to the first day of G-CSF administration, animals were fed water and biscuits containing BrdU as described above. Animals were leukapheresed on the fifth day of G-CSF administration by means of a standard protocol.20,21 The leukaphereses were performed with animals under ketamine sedation (10 mg/kg body weight intramuscular) followed by thiopental (25 µg/kg body weight) induction and general oral endotracheal anesthesia (isoflurane, 1% to 2%). A Cobe spectra leukapheresis unit (Cobe, Lakewood, CO) was primed with approximately 180 mL irradiated whole blood obtained from another ABO-compatible baboon blood donor. Venous access for both the draw and return lines was created by a surgical cut down of the right femoral vein where a double-lumen 7 French pediatric hemodialysis catheter (Medcomp, Harleysville, PA) was inserted. Before leukapheresis, each animal was anticoagulated with heparin (50 U/kg administered as an intravenous bolus following cannulation, followed by a continuous intravenous infusion at a rate of 10 U/kg/h). Acid citrate dextrose (ACD-A) (Baxter/Fenwal, Deerfield, IL) was administered as a continuous intravenous infusion at the rate of 1 mL/25 mL whole blood entering the machine. Flow rates of approximately 20 to 25 mL/min were achieved in order to process approximately 3 blood volumes during the period of leukapheresis. The leukapheresis product (LP) was collected into a single plastic blood collection bag (Baxter) containing 20 mL ACD-A. The CD34+ cells in the LP were analyzed for their incorporation of BrdU.PHSC isolation Every 2 to 5 weeks, bone marrow (BM) samples were obtained from the iliac crests or humeri of chronically BrdU-fed animals (PA6588, PA6589, PA6644) following ketamine (10 mg/kg) and xylazine (1 mg/kg) sedation. The collection and separation of BM cells, PB cells, and cells within the LP were performed as previously described.7 The heparinized BM, PB, or LPs were diluted 1:8 in phosphate-buffered saline (PBS), and the mononuclear cell fraction was obtained by centrifugation over 60% Percoll (Pharmacia, Uppsala, Sweden) at 500g for 30 minutes at room temperature. CD34+ cells were selected from low-density bone marrow cells (LDBMCs) by magnetic activated cell sorting (Miltenyi Biotec, Auburn, CA) by means of a mouse immunoglobulin (Ig)-M monoclonal antibody (mAb) 12-8 (CD34)23 (a gift of Dr Robert G. Andrews, Fred Hutchinson Cancer Research Center, Seattle, WA) and anti-mouse IgM microbeads (Miltenyi Biotec).Hoechst/Rhodamine staining and flow-cytometric isolation of the CD34+ cell subpopulations The fluorescent dyes Hoechst 33342 (Ho) and Rhodamine 123 (Rho) (Molecular Probes, Eugene, OR) were used to obtain subpopulations of CD34+ cells enriched for primitive hematopoietic progenitors.16,24-30 CD34+ cells were suspended at a concentration of 106 cells per milliliter in 0.1 µg/mL Rho and incubated in the dark for 30 minutes at 37°C. The cells were then centrifuged and resuspended in 10 µM Ho and incubated at 37°C for 1 hour in the dark. The cells were washed twice in ice-cold PBS containing 0.2% bovine serum albumin (BSA) (Sigma Chemical) and kept on ice until sorting. Cell sorting was performed by means of a FACSVantage (Becton Dickinson, San Jose, CA). Green fluorescence pulses (Rho) were collected through a fluorescein isothiocyanate (FITC) 530-nm filter, with a bandwidth of 15 nm. UV emissions (Ho) were reflected by a 440 dichroic long pass mirror and collected by a 424DF44 filter. Cells were sorted at a rate of 2000 cells per second and collected in polypropylene tubes containing media with 20% fetal bovine serum (FBS).CD34+ cells that had the least amount of DNA
(HoLow) were arbitrarily subdivided into Rho low
(RhoLow), Rho intermediate (RhoInt), and Rho
high (RhoHi) populations depending on Rho fluorescence, as
previously described.16,24,25 The purity of magnetic
cell-sorted CD34+ cells ranged from 90% to 93%; the
CD34+HoLow/RhoLow cells sorted
flow-cytometrically were virtually 100% pure. The high degree of
purity of the CD34+HoLow/RhoLow
cells was achieved by gating out contaminating mature cells on the
basis of light-scatter properties and excluding HoInt and
HoHi cells (Figure 1).
Sufficient numbers of BM cells were not always available to analyze the
BrdU content of both CD34+ cells and the
CD34+HoLow/RhoLow subpopulation. At
such times, analysis of the BrdU content of CD34+HoLow/RhoLow cells was
considered a priority, and the available CD34+ cells were
devoted to the analysis of the
CD34+HoLow/RhoLow cell
subpopulation.
Colony-forming cell assays Colony-forming cells (CFCs) were assayed under standard conditions in semisolid media as previously described.7 Briefly, 1 × 103 to 2 × 103 cells were plated in duplicate cultures containing 1 mL Iscove's modified Dulbecco's medium (IMDM) with 1.1% methylcellulose, 30% FBS, 5 × 10 5 M 2-mercaptoethanol (Methocult, Stem
Cell Technologies, Vancouver, BC, Canada), to which was added a
cocktail of growth factors, including 100 ng/mL recombinant human stem
cell factor (SCF), 100 ng/mL Flt3 ligand, 10 ng/mL interleukin (IL)-3,
10 ng/mL IL-6, 10 ng/mL granulocyte/macrophage colony stimulating
factor (GM-CSF) (all purchased from R&D Systems, Minneapolis, MN) and 5 U/mL erythropoietin (a gift of Amgen). The cells were plated into 35-mm
tissue-culture dishes (Costar, Corning, NY), and after 14 days'
incubation at 37°C in a 100%-humidified atmosphere containing 5%
CO2, the colonies were scored with an inverted microscope
with the use of standard criteria.7
Cobblestone area-forming cell assays The ability of primitive hematopoietic cells to form cobblestone areas (CAs) in long-term marrow cultures has been used as an in vitro surrogate PHSC assay.7,31,32 Baboon cobblestone area-forming cells (CAFCs) give rise to colonies composed of undifferentiated, uniformly sized, round, refractile cells arranged in a compact manner when cocultured with murine stromal fibroblasts in the presence of human cytokines for 5 weeks.7 BM CD34+ cells or CD34+HoLow/RhoHi, CD34+HoLow/RhoInt, and CD34+HoLow/RhoLow cells were plated in limiting dilution in flat-bottomed 96-well plates (Costar) onto confluent, irradiated (7000 cGy) monolayers of the murine stromal fibroblast line M2-10B4 (a gift of C. Eaves, Vancouver, BC, Canada). Each well contained 200 µL of a 50:50 mixture of IMDM and RPMI with 10% FBS (Hyclone Laboratories, Logan, UT). A cocktail of growth factors, including 100 ng/mL SCF, 100 ng/mL leukemia inhibitory factor (a gift of Amgen), 50 ng/mL IL-3, 50 ng/mL IL-6, and 50 ng/mL GM-CSF, was added to these assays. The cytokine cocktail has been previously shown in our laboratory to be optimal for the development of baboon CAs (data not shown). The cultures were fed weekly by replacement of one half of the culture volume with fresh medium containing the above cytokines at 2 times the previously defined concentration. After 5 weeks of culture in a humidified incubator at 37°C containing 5% CO2, the number of CAs was scored with an inverted microscope by means of standard criteria.32 The CAFC frequency was computed by means of minimization of chi by regression to the cell number at which 37% of wells were negative for CA formation, with 95% statistical precision.33Analysis of BrdU incorporation and propidium iodide staining Analysis of the BrdU content of different subsets of BM cells was performed every 2 to 5 weeks in animals (PA6588, PA6589, and PA6644) continuously fed BrdU. In addition, BM samples from one animal (PA6588) were examined 20 days and then 159 days after the cessation of BrdU administration. Granulocytes and lymphocytes were flow-cytometrically isolated from BM, and their BrdU content was analyzed on the basis of their light-scatter properties. The percentage of BrdU+ cells present in any particular cell subpopulation was flow-cytometrically determined. BrdU incorporation was detected by staining with anti-BrdU mAb conjugated with FITC (Becton Dickinson). The percentage of BrdU+ granulocytes was obtained by subtracting (1) the percentage of granulocytes that nonspecifically bound to the anti-BrdU antibody isolated from a control animal that had not received BrdU from (2) the percentage of BrdU+ BM granulocytes isolated from an animal that had been fed BrdU chronically. The relative mean fluorescence intensity (MFI) of granulocytes and BrdU-pulsed KG1a cells was determined by dividing the geometric mean fluorescence of BrdU-labeled cells by the geometric mean fluorescence of control (BrdU-nonexposed) cells.The number of CD34+ cells and
CD34+HoLow/RhoLow cells that were
BrdU+ at any one time provided a history of PHSC
replication for that particular animal. BrdU staining was performed as
described previously with minor modifications.16,34-36
Briefly, cells were fixed in 70% ethanol; to avoid the formation of
aggregates, the cell suspension was added dropwise onto 70% ethanol
while vortexing and kept on ice for 20 minutes and stored at KG1a cells (purchased from American Type Culture Collection, Rockville, MD), a human myeloid leukemia cell line in an exponential growth phase that had or had not been pulsed with BrdU (10 µM for 40 minutes at 37°C) in vitro served as positive and negative controls, respectively, during BrdU analysis. In addition, LDBMCs that had not been exposed in vitro to BrdU were similarly stained with anti-BrdU/propidium iodide (PI) to serve as an additional negative control. The cell cycle status of the BrdU+ cells was determined by PI (Sigma Chemical) staining. To analyze the DNA content of BrdU+ cells, the cells were stained with 5 µg/mL PI. The BrdU quantitation and DNA content of the cells were analyzed with a FACSCalibur (Becton Dickinson) by means of Cell Quest software (Becton Dickinson). To analyze only the cell cycle status without BrdU labeling, CD34+ cells isolated either from PB, LP, or the BM of baboons were fixed and stained with PI to determine the percentage of cells at different phases of the cell cycle. Data files containing forward- and side-scatter peak signals as well as width and areas of the PI signal were collected. Doublet events were excluded by gating on the PI signal-width channel. The cell cycle analysis was performed with ModFit LT software (Verity Software House, Topham, ME), and at least 20 000 events were collected for analysis of each sample.
Isolation of subpopulations of baboon BM CD34+HoLow cells by intensity of Rho 123 fluorescence Subpopulations of primitive hematopoietic progenitor cells were isolated flow-cytometrically from CD34+HoLow BM cells on the basis of Rho fluorescence (Figure 1). The CD34+HoLow/RhoLow cell population was rare in steady-state BM, representing only 10.4% ± 0.3% (mean ± SE) of the CD34+ selected cells from 12 different samples from 3 animals. The CD34+HoLow/RhoInt and CD34+HoLow/RhoHi cells composed 19.9% ± 2.4% (mean ± SE) and 28.2% ± 3.6% (mean ± SE), respectively, of the total CD34+ cells. The remaining 41.5% ± 4.9% of CD34+ cells were HoHi-HoInt and were more mature cells with a greater quantity of DNA. An analysis of the cell cycle status of CD34+ cells and their subpopulations was performed. In Figure 2, a representative analysis is shown. The CD34+ cell population was largely quiescent with more than 85% of the cells in G0/G1. Increasing numbers of cells resided in G0/G1 as Rho fluorescence diminished, with approximately 96% of CD34+HoLow/RhoLow cells in G0/G1. On the basis of light-scatter properties and Ho/Rho fluorescence, the CD34+HoLowRhoLow cells were judged to be devoid of mature cells and 100% pure. These data directly demonstrate that the CD34+ cell compartment is hierarchically ordered on the basis of quiescence during steady-state conditions.
Cloning efficiency of CD34+ stem cell subpopulations Progenitor cell and CAFC assays were used to determine the proliferative capacity of each of the sorted cell populations. Although each fraction contained significant numbers of progenitor cells and CAFCs (Table 1), the progenitor cell cloning efficiency and CAFC numbers decreased with increasing Rho fluorescence.
In vivo turnover of CD34+HoLow/RhoLow BM cells To determine whether CD34+HoLow/RhoLow cells were dormant or cycled rather slowly during steady-state conditions, BrdU incorporation was monitored over a 21-month period. Hematopoietic cell production was assessed during the period of BrdU administration to detect any deleterious effects of BrdU on hematopoiesis. White blood cell and platelet counts and hematocrit levels of the animals receiving BrdU remained within a normal range throughout the period of study, indicating a lack of documentable hematopoietic toxicity (data not shown).During the year-long period of BrdU labeling, 56% of CD34+
cells in one animal (PA6588) and 84% of CD34+ cells in
another animal (PA6589) underwent self-replication as assessed by BrdU
labeling (Figure 3). The replicative
history of CD34+ BM cells is shown for 52 and 69 weeks for
the 2 animals, respectively, in Figure 3. The labeling of the most
primitive subpopulation of CD34+ cells is shown in Figure
4. Within 11 weeks of BrdU feeding, only
9% of the CD34+HoLow/RhoLow cells
in one of the animals (PA6588) had become BrdU+ while 37%
of the CD34+HoLow/RhoLow cells in
the other animal (PA6589) were BrdU labeled. Although continued BrdU
feeding of one animal (PA6588) never resulted in an increase in the
number of BrdU+
CD34+HoLow/RhoLow cells beyond
26%, continued feeding of BrdU to the second animal (PA6589) led to
increasing numbers of BrdU-labeled
CD34+HoLow/RhoLow cells so that by
week 85, about 70% of this rare cell population had become
BrdU+, indicative of PHSC cycling at an extremely slow rate
(Figure 4). A third baboon (PA6644) received BrdU for a shorter period of time, and 32% of the
CD34+HoLow/RhoLow cells were
labeled BrdU by 18 weeks (Figure 4). The pattern of BrdU labeling was
similar but distinct for each of the animals studied. Such differences
probably represent normal biological variations.
To determine whether these cycling progenitor cells were responsible
for active blood cell production, the BrdU content of BM granulocytes
was repeatedly analyzed. Since granulocytes are derived from relatively
rapidly cycling granulocytic precursors and survive only a few hours,
we believed that BrdU labeling would also serve as an indicator of in
vivo BrdU saturation.37 Within 1 to 2 weeks of BrdU
ingestion, more than 85% to 90% of the granulocytes in the BM had
become BrdU+. Similar degrees of labeling of PB
granulocytes with BrdU were observed (at week 15, in PA6644, 93% of BM
granulocytes were BrdU+ and 98% of PB granulocytes were
BrdU+). This similarity of effect of BM and PB granulocytes
is not surprising since the transit time of BM granulocytes to the PB has been calculated to be 2 to 3 days).37,38 On
an average, 85% to 90% of granulocytes were labeled with BrdU
throughout the period of study (Figure
5A).
To further test the contribution of cycling progenitor cells and/or
PHSCs to blood cell production, BrdU administration was halted after 52 weeks in one of the animals (PA6588). At the time of BrdU withdrawal,
96% of granulocytes had become BrdU+. BM samples were
obtained at 20 days and 159 days after the withdrawal of BrdU. It was
anticipated that after this period of time, free BrdU capable of
labeling newly divided progenitor cells would no longer be
present.22 After 20 days of BrdU withdrawal, 89% of the
granulocytes were BrdU+, while 71% of the granulocytes
remained BrdU+ 159 days after the cessation of BrdU
ingestion (Figure 5B). These findings suggest that the previously
labeled fraction of PHSCs had an extensive proliferative capacity and
was capable of contributing to active blood cell production for
sustained periods of time. At 159 days after the withdrawal of
BrdU, a significant number (29%) of BrdU
In an attempt to quantitate the number of cell divisions required to result in the reduction of MFI, we used, as a model system, KG1a cells, which divide in a predictable fashion. KG1a cells were pulsed for 9 hours, washed, and then cultured in the absence of BrdU for 4 days. Aliquots of cells were analyzed to determine the MFI and the percentage reduction of BrdU+ cells from day 0 to day 4. The relative MFI of BrdU-pulsed cells was determined by dividing the MFI of individual samples by the MFI of a negative control (KG1a cells not pulsed with BrdU). The doubling time of the KG1a cells was measured during their exponential growth phase and was determined to be approximately 22.5 hours. A gradual reduction of the relative MFI (2.5-fold) was observed in BrdU-pulsed KG1a cells over 4 days (Figure 6D-H). Thus, the reduction in relative MFI was estimated to be the result of KG1a cells undergoing approximately 4 cell divisions. We then applied the data generated with KG1a cells to our in vivo baboon model in order to estimate the number of cell divisions required for the reduction of MFI in granulocytes following the withdrawal of BrdU. Following the withdrawal of BrdU (20 days and 159 days), the relative MFI of granulocytes was reduced approximately 9.9-fold and 14.5-fold, respectively, as compared with granulocytes on the day BrdU was halted (Figure 6A-C). This fold reduction of BrdU fluorescence corresponded to a minimum of 15.8 cell divisions (20 days after withdrawal) and 23 cell divisions (159 days after withdrawal) required to achieve the observed reduction in BrdU fluorescence. These findings are a reflection of the extensive proliferative capacity of the PHSCs and progenitor cells previously labeled by long-term BrdU administration. Perturbation of PHSC quiescence by in vivo growth factor administration G-CSF administration results in mobilization of PHSCs into the PB.21,39-43 Stem cell mobilization has been reported to be preceded by PHSC cycling within the BM.18 To test whether the quiescence of PHSCs observed in steady-state BM could be altered by perturbations in the BM microenvironment, G-CSF was administered daily to 2 additional adult baboons (PA6243 and PA5957). During the 5-day period of G-CSF administration, baboons were continuously fed BrdU. Both the LP and BM were analyzed for the presence of BrdU+ cells. Surprisingly, after 5 days of BrdU ingestion, in animals receiving G-CSF (PA5957, PA6243), 66% and 52% of the CD34+ cells, respectively, and 23% and 11% of the CD34+HoLow/RhoLow cells in the LP, respectively, had become BrdU+ (Figure 7). Similarly, when the cytokine-primed BM from one of the animals (PA6243) was analyzed after 5 days of G-CSF administration, 32% of BM CD34+ cells were found to be BrdU+ (data not shown). This contrasts with the longer time required to achieve a similar degree of BrdU labeling of CD34+ or CD34+HoLow/RhoLow cells during steady-state conditions (Figures 3 and 4). To exclude the possibility that any alteration of the phenotype of PHSCs occurred as a consequence of G-CSF administration, we determined the CAFC content of G-CSF mobilized PB CD34+HoLow/RhoHi, CD34+HoLow/RhoInt, and CD34+HoLow/RhoLow cells from both of these animals (PA5957 and PA6243). The number of CAFCs assayed from similar phenotype subpopulations of mobilized PB and BM were compared. The mobilized PB CD34+HoLow/RhoLow cells contained 46 ± 7 CAFCs per 104 cells plated; CD34+HoLow/RhoInt contained 28 ± 23 CAFCs per 104 cells plated, whereas CD34+HoLow/RhoHi cells contained 5 ± 0.5 CAFCs per 104 cells plated. These numbers of mobilized PB CAFCs present were comparable to the number assayed from the same phenotype subpopulations isolated from BM (Table 1). Prior to and following G-CSF administration, the fraction of BM and PB CD34+ cells engaged in active DNA synthesis (S/G2/M) phase was determined.
Prior to the administration of G-CSF, 19% of CD34+ cells
in BM were in the S/G2/M phase of the cell cycle,
while after 5 days of G-CSF administration, a similar proportion of BM
CD34+ cells remained in S/G2/M (15%) (Table
2). By contrast, the CD34+
cells in the LP following G-CSF mobilization were largely quiescent, with more than 98% of the LP CD34+ cells remaining in
G0/G1 (Table 2). The absolute number of
CD34+ cells in the BM at day 0 was 87 CD34+
cells per microliter, and following G-CSF mobilization, it was increased to 449 CD34+ cells per microliter. At day 0, on
the other hand, 1.2 CD34+ cells per microliter were present
in the PB; these increased to 148 CD34+ cells per
microliter following G-CSF administration. Thus, a 5-fold increase in
the absolute number of CD34+ cells in the BM and a 123-fold
increase in the absolute number of CD34+ cells in the
mobilized PB were observed. These findings indicate that G-CSF
treatment induces a fraction of primitive hematopoietic progenitor
cells to enter cell cycle prior to the mobilization. Following
egress into the PB, the vast majority of these progenitor cells
re-enter a quiescent phase.
Our data clearly demonstrate in nonhuman primates that the primitive hematopoietic stem cell compartment remains largely dormant at any one time during steady-state conditions but that these cells do indeed cycle over a relatively long period of time. During the period of study, the fraction of CD34+ cells that were BrdU+ was consistently greater than the CD34+HoLow/RhoLow population. These findings are consistent with the presence of greater numbers of less quiescent, more differentiated progenitor cells in the CD34+ cell population and the enrichment for more quiescent stem cells in CD34+HoLow/RhoLow subpopulation. Although no hematological toxicity was observed in the animals receiving BrdU for several months, it remains possible that the increased incorporation of BrdU over time is a response to BrdU toxicity. Although this possibility is unlikely, it cannot be excluded. Since more than 90% of the granulocytes from these animals were BrdU+ during the observation period, we conclude that the cycling PHSCs or their progenitor cells contribute to active steady-state blood cell production. The continued production of BrdU+ granulocytes 159 days after the cessation of BrdU feeding further suggests that the previously labeled primitive hematopoietic cells continue to contribute to hematopoiesis for several months. The persistent production of BrdU+ granulocytes is the result of the extensive number of cell divisions that the previously labeled PHSCs and progenitor cells were estimated to have undergone following BrdU withdrawal. We have determined that progressively greater numbers of PHSCs do indeed cycle over time. Since we were limited by the number of animals that could be studied, we were unable to calculate the actual doubling time of CD34+HoLow/RhoLow cells. However, the period required for the majority of PHSCs to cycle does appear to be considerably longer than that previously reported in rodents.15-17 The differences in the behavior of rodent and primate PHSCs appear to be primarily a function of the time required for the stem cell compartment to cycle. This slow cycling behavior of baboon PHSCs is in agreement with the data generated by other researchers in other large animal models, including cats and rhesus macaques, and in humans.13,19,44-48 In particular, on the basis of measurements of telomere shortening in humans, Rufer et al44 have previously reported that a rapid expansion of stem cells occurs early in life, followed by a marked decrease in the rate of stem cell divisions in the years that follow. They concluded that 15 to 30 stem cell divisions occur during the first half-year of life followed by less than 1 stem cell division per year in following years. Our finding of slow-cycling PHSCs in adult baboons is consistent with the time frame observed by Rufer and coworkers.44 In this study, the dormant state of the majority of PHSCs in baboons could be dramatically altered by the administration of an external stimulus, G-CSF. As expected, G-CSF resulted in a significant increase in the absolute numbers of CD34+ cells in both BM and PB. Almost 60% of the CD34+ cells and 17% of the CD34+HoLow/RhoLow cells in the LP were BrdU+, suggesting that they had divided prior to their mobilization into the PB. More than 10 weeks were required to achieve a similar degree of BrdU labeling of BM CD34+HoLow/RhoLow cells in animals that had not received G-CSF. The percentage of cycling cells (S/G2/M) in BM at any given time was not increased following G-CSF administration, suggesting that cycling CD34+ cells exit from the BM. Since virtually all of the LP CD34+ cells were in G0/G1, we conclude that the CD34+ cells, which had cycled prior to their exit from the BM, had returned to a quiescent state following their mobilization. These findings are in agreement with previous reports.16,49-51 Since not all LP CD34+ cells and CD34+HoLow/RhoLow cells were BrdU+, BM stem cell cycling appears, in the baboon at least, not to be an absolute requirement for G-CSF mobilization of PHSCs.52 The increased stem cell cycling observed following G-CSF administration suggests that the dormancy status of PHSCs can be modified by extrinsic stimuli. However, our data do indicate that only a small fraction of PHSCs responds to this short course of G-CSF. Whether this proportion would increase with a longer course of G-CSF administration requires further investigation. The intrinsic behavior patterns of baboon and rodent PHSCs are probably genetically determined and might underlie the barriers that have been encountered during attempts to expand PHSCs ex vivo and/or genetically modify large animal PHSCs as compared with rodents.53-58 Although studies of murine hematopoiesis have produced important insights into our fundamental understanding of mammalian blood cell production, the present studies indicate that many of the conclusions derived from rodent studies may not be directly extrapolated to descriptions of the behavior of PHSCs in larger species. Important species-dependent differences in the patterns of PHSC cycling require one to limit conclusions about PHSC behavior to the strain or species in which the data are generated. Whether the differences in stem cell kinetics in large animals as compared with mice represents an evolutionary adaptation to increased size and longevity remains the subject of speculation. The increased numbers of dividing stem cells observed following G-CSF administration, however, may be representative of a variety of potential extrinsic stimuli that might alter PHSC behavior. The behavior of PHSCs during steady-state hematopoiesis and their response to microenvironmental stimuli reported here are best portrayed by a stem cell model in which most PHSCs normally cycle very slowly but remain capable of responding to a variety of environmental stimuli by accelerating this process. Since a cellular hierarchy of PHSCs has been previously reported and also documented here,59-63 it remains possible that the fraction of PHSCs that do not cycle during steady-state conditions or following G-CSF administration might represent the most primitive subpopulation of quiescent PHSCs. Such a model of hematopoiesis, in which there are quiescent and activated PHSCs within the stem cell compartments, has previously been described by Killmann64 (the sleeper-to-feeder stem cell hypothesis). The relevance of this model to large animal steady-state hematopoiesis will require further study.
We thank Manuel B. Borce and Matthew Heckler for their excellent assistance in the administration and daily monitoring of BrdU feeding of the animals; Drs Yi-Hsiang Chen, Amittha Wickrema, and John E. Brandt for their critical reading of the manuscript; Paul A. Weiss for his technical support in FACSVantage sort; and Elen Rosler for her assistance in long-term stem cell culture. N.M. was awarded a post-doctoral fellowship from W. M. Keck Foundation.
Submitted August 21, 2000; accepted January 24, 2001.
C.S. was supported partially by the Pillsburg Foundation and the Living Institute for Surgical Studies.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Ronald Hoffman, Hematology/Oncology Section, University of Illinois College of Medicine, 900 South Ashland Ave, Chicago, IL 60607-7173; e-mail: ronhoff{at}uic.edu.
1.
McCulloch EA, Siminovitich L, Till JE.
Spleen colony formation in anemic mice of genotype wwv.
Science.
1964;144:844-846 2. Hodgson GS, Bradley TR, Radley JM. The organization of hemopoietic tissue as inferred from the effects of 5-fluorouracil. Exp Hematol. 1982;10:26-35[Medline] [Order article via Infotrieve]. 3. Hodgson GS, Bradley TR. In vivo kinetic status of hematopoietic stem and progenitor cells as inferred from labeling with bromodeoxyuridine. Exp Hematol. 1984;12:683-687[Medline] [Order article via Infotrieve]. 4. Lerner C, Harrison DE. 5-Fluorouracil spares hemopoietic stem cells responsible for long-term repopulation. Exp Hematol. 1990;18:114-118[Medline] [Order article via Infotrieve].
5.
Ogawa M.
Differentiation and proliferation of hematopoietic stem cells.
Blood.
1993;81:2844-2853
6.
Keller G, Snodgrass R.
Life span of multipotential hematopoietic stem cells in vivo.
J Exp Med.
1990;171:1407-1418
7.
Brandt JE, Bartholomew AM, Fortman JD, et al.
Ex vivo expansion of autologous bone marrow CD34(+) cells with porcine microvascular endothelial cells results in a graft capable of rescuing lethally irradiated baboons.
Blood.
1999;94:106-113 8. Lajtha LG, Pozzi LV, Schofield R, Fox M. Kinetic properties of hematopoietic stem cells. Cell Tissue Kinet. 1969;2:39-49. 9. Traycoff CM, Orazi A, Ladd AC, Rice S, McMahel J, Srour EF. Proliferation-induced decline of primitive hematopoietic progenitor cell activity is coupled with an increase in apoptosis of ex vivo expanded CD34+ cells. Exp Hematol. 1998;26:53-62[Medline] [Order article via Infotrieve]. 10. Kay HEM. How many cell generations. Lancet. 1965;2:418-419[Medline] [Order article via Infotrieve]. 11. Lemischka IR, Raulet DH, Mulligan RC. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell. 1986;45:917-927[CrossRef][Medline] [Order article via Infotrieve].
12.
Jordan CT, Lemischka IR.
Clonal and systemic analysis of long-term hematopoiesis in the mouse.
Genes Dev.
1990;4:220-232 13. Abkowitz JL, Catlin SN, Guttorp P. Evidence that hematopoiesis may be a stochastic process in vivo. Nat Med. 1996;2:190-197[CrossRef][Medline] [Order article via Infotrieve].
14.
Harrison DE, Lerner C, Hoppe PC, Carlson GA, Alling D.
Large numbers of primitive stem cells are active simultaneously in aggregated embryo chimeric mice.
Blood.
1987;69:773-777
15.
Pietrzyk ME, Priestley GV, Wolf NS.
Normal cycling patterns of hematopoietic stem cell subpopulations: an assay using long-term in vivo BrdU infusion.
Blood.
1985;66:1460-1462 16. Bradford GB, Williams B, Rossi R, Bertoncello I. Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Exp Hematol. 1997;25:445-455[Medline] [Order article via Infotrieve].
17.
Cheshier SH, Morrison SJ, Liao X, Weissman IL.
In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells.
Proc Natl Acad Sci U S A.
1999;96:3120-3125
18.
Morrison SJ, Wright DE, Weissman IL.
Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization.
Proc Natl Acad Sci U S A.
1997;94:1908-1913
19.
Abkowitz JL, Persik MT, Shelton GH, et al.
Behavior of hematopoietic stem cells in a large animal.
Proc Natl Acad Sci U S A.
1995;92:2031-2035
20.
Andrews RG, Bensinger WI, Knitter GH, et al.
The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons.
Blood.
1992;80:2715-2720
21.
Andrews RG, Briddell RA, Knitter GH, Rowley SD, Appelbaum FR, McNiece IK.
Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates.
Blood.
1995;85:15-20 22. Kriss JP, Revesz L. The distribution and fate of bromodeoxyuridine and bromodeoxycytidine in the mouse and rat. Cancer Res. 1962;22:254-265.
23.
Andrews RG, Singer JW, Bernstein ID.
Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors.
Blood.
1986;67:842-845 24. Wolf NS, Kone A, Priestley GV, Bartelmez SH. In vivo and in vitro characterization of long-term repopulating primitive hematopoietic cells isolated by sequential Hoechst 33342-rhodamine 123 FACS selection. Exp Hematol. 1993;21:614-622[Medline] [Order article via Infotrieve]. 25. Leemhuis T, Yoder MC, Grigsby S, Aguero B, Eder P, Srour EF. Isolation of primitive human bone marrow hematopoietic progenitor cells using Hoechst 33342 and Rhodamine 123. Exp Hematol. 1996;24:1215-1224[Medline] [Order article via Infotrieve].
26.
Spangrude GJ, Johnson GR.
Resting and activated subsets of mouse multipotent hematopoietic stem cells.
Proc Natl Acad Sci U S A.
1990;87:7433-7437
27.
Li CL, Johnson GR.
Rhodamine 123 reveals heterogeneity within murine Lin
28.
Zijlmans JM, Visser JW, Kleiverda K, Kluin PM, Willemze R, Fibbe WE.
Modification of rhodamine staining allows identification of hematopoietic stem cells with preferential short-term or long-term bone marrow-repopulating ability.
Proc Natl Acad Sci U S A.
1995;92:8901-8905
29.
Uchida N, Combs J, Chen S, Zanjani E, Hoffman R, Tsukamoto A.
Primitive human hematopoietic cells displaying differential efflux of the rhodamine 123 dye have distinct biological activities.
Blood.
1996;88:1297-1305
30.
Spangrude GJ, Brooks DM, Tumas DB.
Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function.
Blood.
1995;85:1006-1016
31.
Ploemacher RE, van der Sluijs JP, Voerman JSA, Brons NHC.
An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse.
Blood.
1989;74:2755-2763 32. Breems DA, Blokland EA, Neben S, Ploemacher RE. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia. 1994;8:1095-1104[Medline] [Order article via Infotrieve]. 33. Lefkovits I, Waldmann H. Limiting dilution analysis of the cells of immune system, I: the clonal basis of immune response. Immunol Today. 1984;5:265-268.
34.
Gratzner HG.
Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication.
Science.
1982;218:474-475 35. Fogt F, Wan J, O'Hara C, Bistrian BR, Blackburn GL, Istfan NW. Flow cytometric measurement of cell cycle kinetics in rat Walker-256 carcinoma following in vivo and in vitro pulse labelling with bromodeoxyuridine. Cytometry. 1991;12:4133-4135. 36. Mahmud N, Katayama N, Nishii K, et al. Possible involvement of bcl-2 in regulation of cell-cycle progression of haemopoietic cells by transforming growth factor-beta1. Br J Haematol. 1999;105:470-477[CrossRef][Medline] [Order article via Infotrieve]. 37. Robinson WA, Mangalik A. The kinetics and regulation of granulopoiesis. Semin Hematol. 1975;12:7-25[Medline] [Order article via Infotrieve]. 38. Warner HR, Athens JW. An analysis of granulocyte kinetics in blood and bone marrow. Ann N Y Acad Sci. 1967;113:523-536[CrossRef].
39.
Duhrsen U, Villeral JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D.
Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients.
Blood.
1988;72:2074-2081 40. Dreger P, Haferlach T, Eckstein V, et al. G-CSF mobilized peripheral blood progenitor cells for allogenic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol. 1994;87:609-613[Medline] [Order article via Infotrieve].
41.
Bensinger WI, Weaver CH, Appelbaum FR, et al.
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor.
Blood.
1995;85:1655-1658 42. Ho AD, Young D, Maruyama M, et al. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both. Exp Hematol. 1996;24:1460-1468[Medline] [Order article via Infotrieve].
43.
Prosper F, Vanoverbeke K, Stroncek D, Verfaillie CM.
Primitive long-term culture initiating cells (LTC-ICs) in granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells have similar potential for ex vivo expansion as primitive LTC-ICs in steady state bone marrow.
Blood.
1997;89:3991-3997
44.
Rufer N, Brummendorf TH, Kolvraa S, et al.
Telomere fluorescence measurements in granulocytes and T lymphocytes subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood.
J Exp Med
1999;190:157-167
45.
Kim HJ, Tisdale JF, Wu T, et al.
Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates.
Blood.
2000;96:1-8
46.
Nash R, Storb R, Neiman P.
Polyclonal reconstitution of human marrow after allogenic bone marrow transplantation.
Blood.
1988;72:2031-2037 47. Turhan AG, Humphries K, Phillips GL, et al. Clonal hematopoiesis demonstrated by X-linked DNA polymorphisms after allogenic bone marrow transplantaion. N Engl J Med. 1989;320:1655-1661[Abstract].
48.
Prchal JT, Prchal JF, Belickova M, et al.
Clonal stability of blood cell lineages indicated by X-chromosomal transcriptional polymorphism.
J Exp Med.
1996;183:561-567
49.
Roberts AW, Metcalf D.
Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines.
Blood.
1995;86:1600-1605
50.
Lemoli RM, Tafuri A, Fortuna A, et al.
Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor.
Blood.
1997;89:1189-1196
51.
Uchida N, He D, Friera AM, et al.
The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood.
Blood.
1997;89:465-472
52.
To LB, Haylock DN, Dowse T, et al.
A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells.
Blood.
1994;84:2930-2939 53. Hoffman R. Progress in the development of systems for in vitro expansion of human hematopoietic stem cells. Curr Opin Hematol. 1999;6:184-191[CrossRef][Medline] [Order article via Infotrieve].
54.
van Beusechem VW, Kukler A, Heidt PJ, Valerio D.
Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells.
Proc Natl Acad Sci U S A.
1992;89:7640-7644
55.
Bodine DM, Moritz T, Donahue RE, et al.
Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells.
Blood.
1993;82:1975-1980
56.
Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, et al.
Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.
Blood.
1995;85:3048-3057
57.
Xu LC, Karlsson S, Byrne ER, et al.
Long-term in vivo expression of the human glucocerebrosidase gene in nonhuman primates after CD34+ hematopoietic cell transduction with cell-free retroviral vector preparations.
Proc Natl Acad Sci U S A.
1995;92:4372-4376
58.
Donahue RE, Byrn ER, Thomas TE, et al.
Transplantation and gene transfer of the human glucocerebrosidase gene into immunoselected primate CD34+Thy-1+ cells.
Blood.
1996;88:4166-4172 59. Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolated by phenotypes. Immunity. 1994;1:661-673[CrossRef][Medline] [Order article via Infotrieve]. 60. Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoieic stem cell. Science. 1996;273:242-245[Abstract].
61.
Zanjani ED, Almeida-Poroda G, Livingstone AG, Flake AW, Ogawa M.
Human bone marrow CD34 62. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell. 2000;100:157-168[CrossRef][Medline] [Order article via Infotrieve].
63.
Weissman IL.
Translating stem and progenitor cell biology to the clinic: barriers and opportunities.
Science.
2000;287:1442-1446 64. Killmann SA. Acute leukemia: development, remission/relapse pattern, relationship between normal and leukemic hemopoiesis, and the `sleeper-to-feeder' stem cell hypothesis. Ser Haematol. 1968;1:103-128.
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  B. E. Shepherd, H.-P. Kiem, P. M. Lansdorp, C. E. Dunbar, G. Aubert, A. LaRochelle, R. Seggewiss, P. Guttorp, and J. L. Abkowitz Hematopoietic stem-cell behavior in nonhuman primates Blood, September 15, 2007; 110(6): 1806 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O. Ciurea, D. Merchant, N. Mahmud, T. Ishii, Y. Zhao, W. Hu, E. Bruno, G. Barosi, M. Xu, and R. Hoffman Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis Blood, August 1, 2007; 110(3): 986 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Araki, K. Yoshinaga, P. Boccuni, Y. Zhao, R. Hoffman, and N. Mahmud Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential Blood, April 15, 2007; 109(8): 3570 - 3578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Osawa, G. Egawa, S.-S. Mak, M. Moriyama, R. Freter, S. Yonetani, F. Beermann, and S.-I. Nishikawa Molecular characterization of melanocyte stem cells in their niche Development, December 15, 2005; 132(24): 5589 - 5599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Liu, J. Daviau, C. N. Nichols, and D. S. Strayer In vivo gene transfer into rat bone marrow progenitor cells using rSV40 viral vectors Blood, October 15, 2005; 106(8): 2655 - 2662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wagner, A. Ansorge, U. Wirkner, V. Eckstein, C. Schwager, J. Blake, K. Miesala, J. Selig, R. Saffrich, W. Ansorge, et al. Molecular evidence for stem cell function of the slow-dividing fraction among human hematopoietic progenitor cells by genome-wide analysis Blood, August 1, 2004; 104(3): 675 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kuramoto, D. A. Follmann, P. Hematti, S. Sellers, B. A. Agricola, M. E. Metzger, R. E. Donahue, C. von Kalle, and C. E. Dunbar Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates Blood, June 1, 2004; 103(11): 4070 - 4077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Milhem, N. Mahmud, D. Lavelle, H. Araki, J. DeSimone, Y. Saunthararajah, and R. Hoffman Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A Blood, June 1, 2004; 103(11): 4102 - 4110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Persons, J. A. Allay, A. Bonifacino, T. Lu, B. Agricola, M. E. Metzger, R. E. Donahue, C. E. Dunbar, and B. P. Sorrentino Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors Blood, February 1, 2004; 103(3): 796 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. N. Schwartz, B. A. Vance, B. M. Levine, M. Fukazawa, W. G. Telford, D. Cesar, M. Hellerstein, and R. E. Gress Proliferation kinetics of subpopulations of human marrow cells determined by quantifying in vivo incorporation of [2H2]-glucose into DNA of S-phase cells Blood, September 15, 2003; 102(6): 2068 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Baerlocher, J. Mak, A. Roth, K. S. Rice, and P. M. Lansdorp Telomere shortening in leukocyte subpopulations from baboons J. Leukoc. Biol., February 1, 2003; 73(2): 289 - 296. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
20°C in the dark. BrdU was administered continuously to baboons via
their drinking water and food in divided doses. The intake of water and
biscuits containing BrdU was monitored daily. The animals uniformly
ingested the biscuits and water containing BrdU since their alternative
food supply was limited. During the period of study, each animal
ingested between 280 and 330 mg BrdU per day.
indicates PA 5957, 
indicates PA6243.